Skip to main navigation Skip to search Skip to main content

Inhibition of HECT E3 ligases as potential therapy for COVID-19

  • COVID Human Genetic Effort
  • , French COVID Cohort Study Group
  • , CoV-Contact Cohort
  • University of Rome Tor Vergata
  • IRCCS Istituto Neurologico Mediterraneo Neuromed - Pozzilli (IS)
  • University of Nevada, Reno
  • Harvard University
  • IRCCS Istituto per le Malattie Infettive Lazzaro Spallanzani - Roma
  • IRCCS Ospedale pediatrico Bambino Gesù - Roma
  • Boston University
  • Rockefeller University
  • HistoWiz Inc.
  • Icahn School of Medicine at Mount Sinai
  • San Raffaele Roma University
  • Hôpital Avicenne
  • INSERM U1272 Hypoxia & Lung
  • Université Paris 13
  • Université Paris Cité
  • Institut national de la santé et de la recherche médicale
  • National Institutes of Health
  • Desert Research Institute
  • Nevada System of Higher Education
  • University of Toronto
  • Virna Therapeutics
  • Howard Hughes Medical Institute
  • University of Turin

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

SARS-CoV-2 is responsible for the ongoing world-wide pandemic which has already taken more than two million lives. Effective treatments are urgently needed. The enzymatic activity of the HECT-E3 ligase family members has been implicated in the cell egression phase of deadly RNA viruses such as Ebola through direct interaction of its VP40 Protein. Here we report that HECT-E3 ligase family members such as NEDD4 and WWP1 interact with and ubiquitylate the SARS-CoV-2 Spike protein. Furthermore, we find that HECT family members are overexpressed in primary samples derived from COVID-19 infected patients and COVID-19 mouse models. Importantly, rare germline activating variants in the NEDD4 and WWP1 genes are associated with severe COVID-19 cases. Critically, I3C, a natural NEDD4 and WWP1 inhibitor from Brassicaceae, displays potent antiviral effects and inhibits viral egression. In conclusion, we identify the HECT family members of E3 ligases as likely novel biomarkers for COVID-19, as well as new potential targets of therapeutic strategy easily testable in clinical trials in view of the established well-tolerated nature of the Brassicaceae natural compounds.

Original languageEnglish
Article number310
JournalCell Death and Disease
Volume12
Issue number4
DOIs
StatePublished - Apr 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Inhibition of HECT E3 ligases as potential therapy for COVID-19'. Together they form a unique fingerprint.

Cite this